Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial - CNBC
- Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial CNBC
- Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study The Wall Street Journal
- Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal MarketWatch
- Zepbound leads to more weight loss than Wegovy, study finds ABC News